2021 Q4 Form 10-K Financial Statement
#000156459022008060 Filed on March 01, 2022
Income Statement
| Concept | 2021 Q4 | 2021 | 2020 Q4 |
|---|---|---|---|
| Revenue | $3.737M | $18.44M | $5.150M |
| YoY Change | -27.44% | -42.68% | 54.65% |
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $6.688M | $21.97M | $3.110M |
| YoY Change | 115.05% | 69.76% | -2.2% |
| % of Gross Profit | |||
| Research & Development | $21.89M | $75.46M | $14.97M |
| YoY Change | 46.21% | 49.36% | 27.4% |
| % of Gross Profit | |||
| Depreciation & Amortization | $270.0K | $906.0K | $200.0K |
| YoY Change | 35.0% | 41.56% | 33.33% |
| % of Gross Profit | |||
| Operating Expenses | $28.58M | $97.43M | $18.07M |
| YoY Change | 58.14% | 92.84% | 21.03% |
| Operating Profit | -$78.99M | ||
| YoY Change | 152.37% | ||
| Interest Expense | -$242.0K | $105.0K | $590.0K |
| YoY Change | -141.02% | -78.31% | 210.53% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $105.0K | ||
| YoY Change | -95.24% | ||
| Pretax Income | -$25.08M | -$78.89M | -$12.34M |
| YoY Change | 103.24% | 171.19% | 8.15% |
| Income Tax | $484.0K | -$6.000K | -$10.00K |
| % Of Pretax Income | |||
| Net Earnings | -$25.56M | -$78.88M | -$12.32M |
| YoY Change | 107.5% | 173.54% | 8.26% |
| Net Earnings / Revenue | -684.08% | -427.85% | -239.22% |
| Basic Earnings Per Share | -$1.77 | ||
| Diluted Earnings Per Share | -$458.9K | -$1.808M | -$352.0K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 43.63M | ||
| Diluted Shares Outstanding | 43.63M |
Balance Sheet
| Concept | 2021 Q4 | 2021 | 2020 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $551.8M | $551.8M | $177.0M |
| YoY Change | 211.74% | 211.74% | 25.18% |
| Cash & Equivalents | $175.7M | $175.7M | $45.01M |
| Short-Term Investments | $376.1M | $376.1M | $132.0M |
| Other Short-Term Assets | $4.481M | $4.481M | $3.000M |
| YoY Change | 49.37% | 49.37% | 11.11% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | $2.765M | $2.765M | $1.822M |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $559.0M | $559.0M | $181.8M |
| YoY Change | 207.52% | 207.49% | 25.48% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $4.466M | $12.52M | $3.554M |
| YoY Change | 25.66% | 81.48% | 114.1% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $465.0K | $465.0K | $500.0K |
| YoY Change | -7.0% | -7.0% | 150.0% |
| Total Long-Term Assets | $12.99M | $12.99M | $7.403M |
| YoY Change | 75.43% | 75.5% | 161.5% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $559.0M | $559.0M | $181.8M |
| Total Long-Term Assets | $12.99M | $12.99M | $7.403M |
| Total Assets | $572.0M | $572.0M | $189.2M |
| YoY Change | 202.35% | 202.33% | 28.09% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $3.824M | $3.824M | $3.000M |
| YoY Change | 27.47% | 27.47% | 20.0% |
| Accrued Expenses | $10.38M | $10.38M | $8.000M |
| YoY Change | 29.75% | 29.75% | 26.98% |
| Deferred Revenue | $3.642M | ||
| YoY Change | -87.76% | ||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $14.32M | $14.32M | $14.78M |
| YoY Change | -3.11% | -3.23% | -65.93% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | -100.0% | ||
| Other Long-Term Liabilities | $7.652M | $7.652M | $3.100M |
| YoY Change | 146.84% | 146.84% | 106.67% |
| Total Long-Term Liabilities | $7.652M | $7.652M | $3.100M |
| YoY Change | 146.84% | 146.84% | -71.53% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $14.32M | $14.32M | $14.78M |
| Total Long-Term Liabilities | $7.652M | $7.652M | $3.100M |
| Total Liabilities | $21.97M | $21.97M | $17.83M |
| YoY Change | 23.23% | 23.45% | -68.0% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$357.4M | -$278.5M | |
| YoY Change | 28.32% | 11.55% | |
| Common Stock | $900.7M | $443.1M | |
| YoY Change | 103.26% | 32.31% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $550.0M | $550.0M | $171.4M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $572.0M | $572.0M | $189.2M |
| YoY Change | 202.35% | 202.33% | 28.09% |
Cashflow Statement
| Concept | 2021 Q4 | 2021 | 2020 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$25.56M | -$78.88M | -$12.32M |
| YoY Change | 107.5% | 173.54% | 8.26% |
| Depreciation, Depletion And Amortization | $270.0K | $906.0K | $200.0K |
| YoY Change | 35.0% | 41.56% | 33.33% |
| Cash From Operating Activities | -$20.71M | -$69.50M | -$13.11M |
| YoY Change | 57.97% | 44.42% | -166.25% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$514.0K | -$2.050M | -$830.0K |
| YoY Change | -38.07% | -177.74% | 40.68% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | -$214.9M | -$244.7M | $44.02M |
| YoY Change | -588.23% | 1624.59% | -173.71% |
| Cash From Investing Activities | -$215.4M | -$246.8M | $43.20M |
| YoY Change | -598.69% | 1366.77% | -171.62% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 324.0M | 447.5M | 50.00K |
| YoY Change | 647806.0% | 421.64% | -99.82% |
| NET CHANGE | |||
| Cash From Operating Activities | -20.71M | -69.50M | -13.11M |
| Cash From Investing Activities | -215.4M | -246.8M | 43.20M |
| Cash From Financing Activities | 324.0M | 447.5M | 50.00K |
| Net Change In Cash | 87.81M | 130.7M | 30.14M |
| YoY Change | 191.34% | 545.2% | -330.08% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$20.71M | -$69.50M | -$13.11M |
| Capital Expenditures | -$514.0K | -$2.050M | -$830.0K |
| Free Cash Flow | -$20.20M | -$67.45M | -$12.28M |
| YoY Change | 64.46% | 32.88% | -160.26% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
205931 | |
| CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
13.01 | |
| CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
5638232 | |
| CY2021Q4 | us-gaap |
Common Stock No Par Value
CommonStockNoParValue
|
||
| CY2021 | us-gaap |
Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
|
Unlimited | |
| CY2021 | us-gaap |
Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
|
Unlimited | |
| CY2021 | us-gaap |
Tax Credit Carryforward Expiration Date
TaxCreditCarryforwardExpirationDate
|
2041-12-31 | |
| CY2021Q4 | us-gaap |
Preferred Stock No Par Value
PreferredStockNoParValue
|
||
| CY2021Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2021Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P10Y6M | |
| CY2020Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P6Y6M | |
| CY2021 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y3M3D | |
| CY2021 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y7M28D | |
| CY2021 | dei |
Security12b Title
Security12bTitle
|
Common Shares, without par value | |
| CY2021Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
13717000 | |
| CY2020Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
10874000 | |
| CY2021 | dei |
Trading Symbol
TradingSymbol
|
XENE | |
| CY2021 | dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | |
| CY2021 | dei |
Auditor Firm
AuditorFirmId
|
85 | |
| CY2021 | dei |
Auditor Name
AuditorName
|
KPMG LLP | |
| CY2021 | dei |
Auditor Location
AuditorLocation
|
Vancouver, BC, Canada | |
| CY2021Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
175688000 | |
| CY2020Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
45009000 | |
| CY2021Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
376086000 | |
| CY2020Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
131988000 | |
| CY2021Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
2765000 | |
| CY2020Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
1822000 | |
| CY2021Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
4481000 | |
| CY2020Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2964000 | |
| CY2021Q4 | us-gaap |
Assets Current
AssetsCurrent
|
559020000 | |
| CY2020Q4 | us-gaap |
Assets Current
AssetsCurrent
|
181783000 | |
| CY2021Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
8056000 | |
| CY2020Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
3326000 | |
| CY2021Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
4466000 | |
| CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
3554000 | |
| CY2021Q4 | us-gaap |
Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
|
465000 | |
| CY2020Q4 | us-gaap |
Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
|
523000 | |
| CY2021Q4 | us-gaap |
Assets
Assets
|
572007000 | |
| CY2020Q4 | us-gaap |
Assets
Assets
|
189186000 | |
| CY2020Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
3642000 | |
| CY2021Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
605000 | |
| CY2020Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
265000 | |
| CY2020Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
14781000 | |
| CY2021Q4 | us-gaap |
Liabilities
Liabilities
|
21974000 | |
| CY2021Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
1016000 | |
| CY2021Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
1016000 | |
| CY2021Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
7732000 | |
| CY2021Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
51634752 | |
| CY2021Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
51634752 | |
| CY2021Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
783170000 | |
| CY2021Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
117495000 | |
| CY2021Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-357374000 | |
| CY2021Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-990000 | |
| CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
550033000 | |
| CY2021Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
572007000 | |
| CY2021 | us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
-719000 | |
| CY2020 | us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
4000 | |
| CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-28837000 | |
| CY2020 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
102456000 | |
| CY2020 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
5677000 | |
| CY2020 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
82000 | |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
171355000 | |
| CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-78882000 | |
| CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
12.55 | |
| CY2020 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
216000 | |
| CY2020 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
-988000 | |
| CY2020 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
2022000 | |
| CY2021 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-3642000 | |
| CY2020 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-26810000 | |
| CY2020 | us-gaap |
Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
|
-16743000 | |
| CY2021 | xene |
Proceeds From Issuance Of Common Shares And Pre Funded Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonSharesAndPreFundedWarrantsNetOfIssuanceCosts
|
447283000 | |
| CY2020 | xene |
Proceeds From Issuance Of Common Shares And Pre Funded Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonSharesAndPreFundedWarrantsNetOfIssuanceCosts
|
102456000 | |
| CY2020 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
82000 | |
| CY2020 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
85795000 | |
| CY2021 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-592000 | |
| CY2020 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-593000 | |
| CY2021 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
130679000 | |
| CY2020 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
20254000 | |
| CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
45009000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
24755000 | |
| CY2020 | us-gaap |
Interest Paid Net
InterestPaidNet
|
339000 | |
| CY2021 | us-gaap |
Interest Income Deposits With Financial Institutions
InterestIncomeDepositsWithFinancialInstitutions
|
3517000 | |
| CY2020 | us-gaap |
Interest Income Deposits With Financial Institutions
InterestIncomeDepositsWithFinancialInstitutions
|
4115000 | |
| CY2021 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
824000 | |
| CY2020 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
634000 | |
| CY2021 | xene |
Fair Value Of Stock Options Exercised On Cashless Basis
FairValueOfStockOptionsExercisedOnCashlessBasis
|
3349000 | |
| CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
105405000 | |
| CY2020 | xene |
Increase In Operating Lease Right Of Use Asset And Operating Lease Liability Related To Lease Amendment
IncreaseInOperatingLeaseRightOfUseAssetAndOperatingLeaseLiabilityRelatedToLeaseAmendment
|
2907000 | |
| CY2020 | xene |
Fair Value Of Stock Options Exercised On Cashless Basis
FairValueOfStockOptionsExercisedOnCashlessBasis
|
887000 | |
| CY2021 | xene |
Increase In Operating Lease Liability And Accounts Receivable Related To Lease Incentives Claimed In The Period
IncreaseInOperatingLeaseLiabilityAndAccountsReceivableRelatedToLeaseIncentivesClaimedInThePeriod
|
493000 | |
| CY2021 | xene |
Increase In Operating Lease Right Of Use Asset And Operating Lease Liability Related To Lease Amendment
IncreaseInOperatingLeaseRightOfUseAssetAndOperatingLeaseLiabilityRelatedToLeaseAmendment
|
5248000 | |
| CY2021Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-357374000 | |
| CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-78882000 | |
| CY2021 | us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.52%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Basis of presentation:<span style="font-weight:normal;"> </span></p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:3.52%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These consolidated financial statements are presented in U.S. dollars and have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”). Certain information has been reclassified to conform with the financial statement presentation adopted for the current year.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:3.52%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has one wholly-owned subsidiary as of December 31, 2021, Xenon Pharmaceuticals USA Inc., which was incorporated in Delaware on December 2, 2016.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:3.52%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany transactions and balances have been eliminated on consolidation. </p> | |
| CY2021 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.52%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:2.59%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Use of estimates: </p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:7.03%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires <span style="Background-color:#FFFFFF;color:#000000;">management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant areas of estimates include, but are not limited to, revenue recognition including estimated timing of completion of performance obligations and the determination of stock-based compensation. These estimates and assumptions take into account historical and forward looking factors that the Company believes are reasonable, including but not limited to the potential impacts arising from the coronavirus (“COVID-19”) and pandemic public and private sector policies and initiatives aimed at reducing its transmission. The full extent to which the pandemic may have a direct or indirect impact on the Company’s business, results of operations and financial condition, including revenue, expenses, research and clinical development plans and timelines, depends on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19, as well as the economic impact on local, regional, national and global markets. There was no material impact to the Company’s consolidated financial statements as of and for the years ended December 31, 2021 and 2020. Estimates and assumptions are reviewed quarterly. All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</span></p> | |
| CY2021 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | |
| CY2020 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | |
| CY2021 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.52%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:2.59%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Concentration of credit risk and of significant customers: </p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:7.03%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents were held at major financial institutions in Canada and the United States. Such deposits may be in excess of insured limits in the event of non-performance by the institutions; however, the Company does not anticipate non-performance. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:7.03%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neurocrine Biosciences, Inc. ("Neurocrine Biosciences") and Pacira BioSciences, Inc. (“Pacira BioSciences”) accounted for 84% and 16% of revenue recognized for the year ended December 31, 2021, respectively. Neurocrine Biosciences accounted for 100% of revenue recognized for the year ended December 31, 2020.</p> | |
| CY2021 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2020Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
15154000 | |
| CY2021Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
4466000 | |
| CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
3554000 | |
| CY2020 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
536000 | |
| CY2021 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
751000 | |
| CY2020 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
549000 | |
| CY2021Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0342 | |
| CY2020Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0245 | |
| CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
879000 | |
| CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
932000 | |
| CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
974000 | |
| CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
1029000 | |
| CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
|
1083000 | |
| CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
|
6793000 | |
| CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
11690000 | |
| CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
1965000 | |
| CY2021Q4 | xene |
Future Lease Incentives Reasonably Certain Of Use
FutureLeaseIncentivesReasonablyCertainOfUse
|
1468000 | |
| CY2021Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
8257000 | |
| CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
2966643 | |
| CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
2966643 | |
| CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
8.85 | |
| CY2021Q4 | us-gaap |
Accounts Payable Trade Current
AccountsPayableTradeCurrent
|
3824000 | |
| CY2021Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
5940000 | |
| CY2021Q4 | xene |
Accrued Consulting And Contracted Research Current
AccruedConsultingAndContractedResearchCurrent
|
3550000 | |
| CY2021Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
285000 | |
| CY2021Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
118000 | |
| CY2021Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
13717000 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
3534236 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
7.90 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
19618000 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1482250 | |
| CY2020 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
171812 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
1535000 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
85677 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
13.04 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
4758997 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
9.10 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
30464000 | |
| CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1775450 | |
| CY2021 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
19.82 | |
| CY2021 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
690284 | |
| CY2021 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
7.34 | |
| CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
11306000 | |
| CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
8.85 | |
| CY2021Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
66418000 | |
| CY2021Q4 | us-gaap |
Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
|
0.79 | |
| CY2021 | xene |
Stock Options Exercised For Number Of Common Shares For Cash
StockOptionsExercisedForNumberOfCommonSharesForCash
|
66215 | |
| CY2020 | xene |
Stock Options Exercised For Number Of Common Shares For Cash
StockOptionsExercisedForNumberOfCommonSharesForCash
|
26513 | |
| CY2021 | xene |
Common Stock Issued For Cashless Exercise
CommonStockIssuedForCashlessExercise
|
412940 | |
| CY2020 | xene |
Common Stock Issued For Cashless Exercise
CommonStockIssuedForCashlessExercise
|
87197 | |
| CY2021 | xene |
Cashless Exercise Of Stock Options
CashlessExerciseOfStockOptions
|
624069 | |
| CY2020 | xene |
Cashless Exercise Of Stock Options
CashlessExerciseOfStockOptions
|
145299 | |
| CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
12.55 | |
| CY2021Q4 | us-gaap |
Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
|
0.79 | |
| CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
12.54 | |
| CY2021Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
|
10.56 | |
| CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
3698000 | |
| CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.0000 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.0000 | |
| CY2021 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
10017000 | |
| CY2021Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
24210000 | |
| CY2021 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y9M10D | |
| CY2021Q4 | xene |
Warrants Exercise Description
WarrantsExerciseDescription
|
The Company may not affect the exercise of any Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any Pre-Funded Warrant that, upon giving effect to such exercise, would cause: (i) the aggregate number of common shares beneficially owned by such holder, together with its affiliates, to exceed 4.99% of the total number of common shares outstanding immediately after giving effect to the exercise; or (ii) the combined voting power of the Company’s securities beneficially owned by such holder, together with its affiliates, to exceed 4.99% of the combined voting power of all of the Company’s securities immediately outstanding after giving effect to the exercise, which percentage may be changed at the holder’s election to a higher or lower percentage not in excess of 19.99% upon at least 61 days’ notice to the Company. | |
| CY2021Q1 | xene |
Warrants Exercise Description
WarrantsExerciseDescription
|
The Company may not affect the exercise of any Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any Pre-Funded Warrant that, upon giving effect to such exercise, would cause: (i) the aggregate number of common shares beneficially owned by such holder, together with its affiliates, to exceed 4.99% of the total number of common shares outstanding immediately after giving effect to the exercise; or (ii) the combined voting power of the Company’s securities beneficially owned by such holder, together with its affiliates, to exceed 4.99% of the combined voting power of all of the Company’s securities immediately outstanding after giving effect to the exercise, which percentage may be changed at the holder’s election to a higher or lower percentage not in excess of 19.99% upon at least 61 days’ notice to the Company. | |
| CY2021Q4 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
|
2775996 | |
| CY2021 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-6000 | |
| CY2020 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-257000 | |
| CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.27 | |
| CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.27 | |
| CY2021 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-21300000 | |
| CY2020 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-7856000 | |
| CY2021 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
21354000 | |
| CY2020 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
7821000 | |
| CY2020 | us-gaap |
Income Tax Reconciliation Tax Credits Investment
IncomeTaxReconciliationTaxCreditsInvestment
|
1689000 | |
| CY2021 | us-gaap |
Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
|
2033000 | |
| CY2020 | us-gaap |
Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
|
1135000 | |
| CY2021 | us-gaap |
Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
|
-506000 | |
| CY2020 | us-gaap |
Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
|
-432000 | |
| CY2021Q4 | xene |
Deferred Tax Assets Scientific Research And Development
DeferredTaxAssetsScientificResearchAndDevelopment
|
32505000 | |
| CY2020Q4 | xene |
Deferred Tax Assets Scientific Research And Development
DeferredTaxAssetsScientificResearchAndDevelopment
|
29580000 | |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
27271000 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
25411000 | |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
53453000 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
35803000 | |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
|
7667000 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
|
6635000 | |
| CY2021Q4 | xene |
Deferred Tax Assets Deferred Financing Fees
DeferredTaxAssetsDeferredFinancingFees
|
7252000 | |
| CY2020Q4 | xene |
Deferred Tax Assets Deferred Financing Fees
DeferredTaxAssetsDeferredFinancingFees
|
1689000 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
|
983000 | |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
826000 | |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
128509000 | |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
465000 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
523000 | |
| CY2021 | us-gaap |
Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
|
120388000 | |
| CY2020 | us-gaap |
Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
|
109556000 | |
| CY2021Q4 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
197976000 | |
| CY2020Q4 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
132604000 | |
| CY2021Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
10850000 | |
| CY2020Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
10850000 |
